Cristina Gasparetto, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address gaspa001@mc.duke.edu

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Education and Training

  • Fellow in Hematology/Oncology, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.D., Sapienza University of Rome (Italy), 1986

Publications

Stadtmauer, Edward A., Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial..” J Clin Oncol 37, no. 7 (March 1, 2019): 589–97. https://doi.org/10.1200/JCO.18.00685.

PMID
30653422
Full Text

Zheng, Jing, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick, Jagadish Kummetha Venkta, Cleopatra Kozlowski, et al. “Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade..” Cancer Lett 440–441 (January 2019): 1–10. https://doi.org/10.1016/j.canlet.2018.10.003.

PMID
30312729
Full Text

Bahlis, Nizar J., Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, et al. “Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma..” Blood 132, no. 24 (December 13, 2018): 2546–54. https://doi.org/10.1182/blood-2018-06-858852.

PMID
30352784
Full Text

Abonour, Rafat, Lynne Wagner, Brian G. M. Durie, Sundar Jagannath, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, et al. “Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry..” Ann Hematol 97, no. 12 (December 2018): 2425–36. https://doi.org/10.1007/s00277-018-3446-y.

PMID
30056582
Full Text

Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma..” Blood Cancer J 8, no. 8 (July 31, 2018). https://doi.org/10.1038/s41408-018-0104-5.

PMID
30065277
Full Text

Jagannath, Sundar, Rafat Abonour, Brian G. M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, et al. “Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)..” Clin Lymphoma Myeloma Leuk 18, no. 7 (July 2018): 480-485.e3. https://doi.org/10.1016/j.clml.2018.04.007.

PMID
29844008
Full Text

Rifkin, Robert M., Sundar Jagannath, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, et al. “Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry..” Clin Ther 40, no. 7 (July 2018): 1193-1202.e1. https://doi.org/10.1016/j.clinthera.2018.05.017.

PMID
30007443
Full Text

Sundaramoorthy, Pasupathi, Cristina Gasparetto, and Yubin Kang. “The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation..” Cancer Med, May 15, 2018. https://doi.org/10.1002/cam4.1543.

PMID
29761903
Full Text

Kumar, S. K., A. Dispenzieri, R. Fraser, F. Mingwei, G. Akpek, R. Cornell, M. Kharfan-Dabaja, et al. “Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time..” Leukemia 32, no. 4 (April 2018): 986–95. https://doi.org/10.1038/leu.2017.331.

PMID
29263438
Full Text

Pages